Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Biocon Collaborates with Advaxis for 'ADXS-HPV' A Novel Cancer Immunotherapy

Business Wire January 22, 2014

Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study

Business Wire January 21, 2014

Advaxis, Inc. - "Welcome to the Advaxis CEO Blog"

Accesswire January 15, 2014

Advaxis Launches Online Communication Channels

Business Wire January 15, 2014

Advaxis to Present at Biotech Showcase(TM) 2014 in San Francisco

Business Wire January 8, 2014

Advaxis Approved to Receive Cash Allocation Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Business Wire December 12, 2013

Five Star Equities Issues New Research Reports on ADXS, CNDO, DRWI and KNDI

Accesswire December 10, 2013

Advaxis Signs Exclusive Licensing Agreement for Development and Commercialization of ADXS-HPV in Asia

Business Wire December 9, 2013

Advaxis Cancer Immunotherapy Featured on ABC News

Business Wire November 22, 2013

Advaxis Reports Final 18-Month Survival Data for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 8, 2013

Advaxis' ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer

Business Wire November 5, 2013

Advaxis Appoints Gregory T. Mayes as Chief Operating Officer

Business Wire October 28, 2013

Advaxis Announces First Patient Dosed with ADXS-HPV in Head and Neck Cancer Study

Business Wire October 23, 2013

Advaxis Announces Closing of Public Offering of Common Stock and Warrants

Business Wire October 22, 2013

Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option

Business Wire October 18, 2013

Advaxis Announces Pricing of Public Offering of Common Stock and Warrants

Business Wire October 16, 2013

FNMA, WTER, ADXS and FMCC added to OTC Active Stock Watch List at EPR

Accesswire September 12, 2013

Advaxis Lead Product Candidate ADXS-HPV in Combination with PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study

Business Wire September 5, 2013

Advaxis Announces Three Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer Annual Meeting

Business Wire September 3, 2013

Advaxis Appoints Daniel J. O'Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board

Business Wire August 20, 2013